Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with active severe alopecia areata exhibited decreased CD200 expression on T and B lymphocytes, which may be linked to an imbalance in Th1/Th2 immune equilibrium.

This study found that antroquinonol inhibited CD8+ T cell proliferation and reduced proinflammatory cytokine secretion in vitro, while also ameliorating H2O2-induced depigmentation and resisting reductions in hair follicle length, skin thickness, and tyrosinase expression in mice.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

This study found that platelet-rich plasma had limited efficacy in treating alopecia areata but may help restore immune balance in the affected areas.

This case report describes a patient with Crohn's disease developing alopecia and psoriasiform skin lesions while on adalimumab treatment.

This paper proposes that the induction of HF-specific neo-antigens by peripheral CD8+ T cells may maintain self-tolerance but could also lead to immunopathology in conditions like alopecia areata.

This case report detailed alopecia universalis developing shortly after hepatitis C treatment with peg-interferon, ribavirin, and telaprevir, suggesting potential immune-related links between interferon treatment and alopecia areata.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

In this study, researchers found that patients with alopecia areata had a significant increase in NKG2D+CD4+ T cell levels in their blood compared to healthy controls.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This case report describes a 56-year-old woman with rheumatoid arthritis who developed alopecia universalis during treatment with the TNF inhibitor adalimumab, with no hair regrowth after stopping the medication.

This study suggests that immune privilege guardians and the pro-inflammatory cytokine interferon-γ significantly influence the dynamics of alopecia areata, supporting the hypothesis that immune privilege collapse is crucial in its development.

This study found that topical ginsenoside Rg1 may protect skin from UVB-induced damage in mice by reducing pathological changes and modulating cytokine mRNA expression associated with inflammation and immune response.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This article reviews the promising ease of drug administration via transdermal and other topical routes, highlighting their potential for high patient compliance and reduced side effects but provides no new clinical results.

This study found that topical application of Astragalus membranaceus extract induced hair regrowth and reduced immune response markers in mice with natural hair loss.

Sorafenib may cause hair loss in a way similar to alopecia areata.

In this animal study, a herbal preparation demonstrated moderate anti-inflammatory and immunomodulating properties, suggesting its potential usefulness for preventing and treating alopecia.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

This study discusses the epithelial-immune microenvironment in chronic skin diseases, such as psoriasis and atopic dermatitis, and highlights current and future treatment strategies targeting inflammatory loops within these diseases.

This research suggests that innate lymphoid cells type 1 (ILC1) may contribute to the development of alopecia areata, alongside CD8+ T cells, by disrupting hair follicle immune privilege and promoting features of the disease.

This study suggests that IL-17 may play a more significant role than IFN-γ in the pathogenesis of chronic alopecia areata, with increasing severity linked to Th17 lymphocytes and cytotoxic T lymphocyte infiltration.

This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

The document concludes that doctors should monitor children's brain development when treating hemangiomas with interferon alfa and consider stopping the treatment if problems arise, while also exploring drugs that might counteract side effects.

This report presents a case where multiple steatocystomas appeared in a psoriatic patient during ustekinumab treatment, suggesting the drug may unmask a genetic predisposition to steatocystoma multiplex.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.